TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05138146
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg/m2 or 75mg/m2, IV, Day1of the1-6th treatment cycles only. Every 3 weeks a treatment cycle.
Study: NCT05574374
Drug: DWP14012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium-competitive acid blocker
Study: NCT05574374
Drug: DWC202202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel Bisulfate
Study: NCT05574374
Drug: DWC202203
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor
Study: NCT06279507
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride 2 mL prepared in plastic syringe
Study: NCT05536011
Drug: Comparator Products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to at least one dose of a comparator product at any time during pregnancy
Study: NCT05764603
Drug: MRI
Normalized name: Amrit
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR ARTHROGRAPHY AND CT ARTHROGRAPHY IN PATIENT WITH KNEE OSTEOARTHRITIS
Study: NCT05084261
Drug: BT051 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral BT051 200 mg once daily for 28 days.
Study: NCT05084261
Drug: BT051 800 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral BT051 800 mg once daily for 28 days.
Study: NCT05084261
Drug: BT051 3200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral BT051 3200 mg once daily for 28 days.
Study: NCT05084261
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Matching BT051
Study: NCT05423951
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the study period, a total dose of sufentanil 0.5-2.0 mcg/kg was intravenously administered at the attending anesthesiologists' discretion.
Study: NCT05932888
Drug: QLM3003
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1%（10g∶0.1g）or 1.5%（10g∶0.15g）or 2%（10g∶0.2g）
Study: NCT05932888
Drug: QLM3003 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1%（10g∶0.1g）or 1.5%（10g∶0.15g）or 2%（10g∶0.2g）(matching corresponding study medication)
Study: NCT05008861
Drug: Anti-programmed cell death protein 1/programmed death-ligand 1 monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of one of anti-PD-1/PD-L1 mAbs administered as a 1 hour infusion every 3 weeks.
Study: NCT05469984
Drug: ampicillin plus gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin
Study: NCT04421248
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In ADHD participants only: blinded, randomized, placebo-controlled, single dose, crossover on separate days separated by at least one week.
Study: NCT04690530
Drug: Sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: sedation wil be performed
Study: NCT06410443
Drug: Antibiotics, probiotics, vitamins, antidiarrheal drugs, enteral nutrition, and endoscopic argon plasma coagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment according to guideline of radiation-induced intestinal injury.
Study: NCT05021094
Drug: Kuntai Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The instructions is pointed that each Kuntai capsule is 0.5g and the usage of Kuntai capsule is oral taking 4 capsules each time, 3 times a day, and 4 weeks is a course of treatment. The patients will taking 3 courses of treatment in this study.
Study: NCT05021094
Drug: Femoston
Approvals — FDA: no, EMA: no, PMDA: no
Description: The estrogen and progesterone sequential regimen was adopted. The Femoston was contain estradiol tablets and estradiol didroxyprogesterone tablets. Red tablets (estradiol, 2 mg/d) were taken in the first 14 days, and gray tablets (estradiol, 2 mg/d, dydrogesterone,10 mg/d) were taken in the last 14 days. 28 days was a course of treatment, and three courses of treatment were taken. The patients will taking 3 courses of treatment in this study.
Study: NCT05235438
Drug: IMM27M
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMM27M injection
Study: NCT05817162
Drug: Ringer's Lactate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringers lactate solution is used during arthrocentesis to wash out the joint inflammatory cells and to release the stuck disc phenomenon.
Study: NCT06525519
Drug: ATLG
Normalized name: Antithymocyte Globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg/day IV for 4 consecutive days (day-5 to -2 before transplantation). All transplant recipients will receive myeloablative conditioning or modified myoloablative conditioning and standard GVHD prophylaxis.
Study: NCT06525519
Drug: ATLG
Normalized name: Antithymocyte Globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5mg/kg/day IV for 4 consecutive days (day-5 to -2 before transplantation). All transplant recipients will receive myeloablative conditioning or modified myoloablative conditioning and standard GVHD prophylaxis.
Study: NCT06134063
Drug: Xuanfei Baidu granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuanfei Baidu granule will be administered twice daily for 7 days on the basis of basic treatment
Study: NCT06134063
Drug: Xuanfei Baidu granule Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuanfei Baidu granule Placebo will be administered twice daily for 7 days on the basis of basic treatment
Study: NCT05323396
Drug: Antiparasitic medication
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants in the parasite-positive group (based on positive result of either stool microscopy, stool PCR, or Strongyloides IgG) will be administered antiparasitic treatment. Antiparasitic medication administered will be targeted to treat the parasite identified. See detailed description of protocol for medication, dose, and frequency that will be given for each parasitic infection identified.~Participants with stool microscopy, stool PCR, and Strongyloides IgG all negative will not be administered treatment, thus will serve as controls.
Study: NCT04710160
Drug: Novel fast-setting calcium silicate cement (Protooth)
Normalized name: Calcium Silicate
DrugBank: Calcium silicate (DB13829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In form of power and liquid to be mixed together to form a paste.
Study: NCT05396677
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 500 mg acetaminophen (one time)
Study: NCT05677867
Drug: Formulation A (PF-07081532 20 mg plus 60 mg)
Normalized name: codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formulation A: administered as a 20 mg immediate release tablet and a 60 mg immediate release tablet
Study: NCT05677867
Drug: Formulation B (PF-07081532 80 mg)
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B: administered as a 80 mg immediate release tablet
Study: NCT05352646
Drug: Autologous memory lymphocyte Injection (NewishT), low-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recruited participants in low-dose group will receive autologous memory lymphocyte (NewishT) intravenous infusion every 4 weeks, a total of 2 times.
Study: NCT05352646
Drug: Autologous memory lymphocyte Injection (NewishT), high-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recruited participants in high-dose group will receive autologous memory lymphocyte (NewishT) intravenous infusion every 2 weeks, a total of 4 times.
Study: NCT05645198
Drug: Oozfix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly apply carboxymetyl starch (Oozfix) 5 gram evenly at the suprapancreatic surgical bed after gastrectomy
Study: NCT05645198
Drug: Greenplast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly apply Greenplast (Aprotinin 1000kIU/mL, Thrombin 500IU/mL, Fibrinogen 95mg/mL) 4 gram evenly at the suprapancreatic surgical bed after gastrectomy
Study: NCT06132126
Drug: LY3938577
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT06132126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05302388
Drug: SIBP-R002
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIBP-R002: injection; strength: 1, 2, 4, 8 or 12 mg; dose escalation and the first group is 1mg (intravenous infusion, 5 groups, the first group consisted of four people, and the other groups consisted of eight).
Study: NCT05302388
Drug: Dexamethasone or Methyl prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion, 5mg or 1\~2mg/kg. These were administered within 30 minutes prior to infusion of the experimental drug.
Study: NCT05302388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same volume of placebo as SIBP-R002: injection; strength: the same volume of placebo as SIBP-R002 of 1, 2, 4, 8 or 12 mg (intravenous infusion, 5 groups, the first group consisted of one people, and the other groups consisted of two). The rule and dose of placebo were the same as SIBP-R002.
Study: NCT04626323
Drug: Best medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will also receive standard of care medical therapy for DKD (ACEI or ARB + SGLT2i) and T2DM (metformin, glitazones, incretin therapy - DPP4 inhibitor and GLP-1 analogs - and insulin, if necessary).
Study: NCT04889040
Drug: RO7496998
Approvals — FDA: no, EMA: no, PMDA: no
Description: 275 mg tablets
Study: NCT04889040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching tablets
Study: NCT04942730
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg iv x 2 days, Days +3 through +4
Study: NCT06121115
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine administered in midline catheter according to clinical routine
Study: NCT05864261
Drug: JT1801 60ug
Approvals — FDA: no, EMA: no, PMDA: no
Description: JT1801, 60ug, IV injection
Study: NCT05864261
Drug: NESP 60ug
Approvals — FDA: no, EMA: no, PMDA: no
Description: NESP, 60ug, IV injection
Study: NCT04698941
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg daily oral tablet taken.
Study: NCT05363202
Drug: Matching Placebo inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation
Study: NCT06551740
Drug: HUC2-344
Approvals — FDA: no, EMA: no, PMDA: no
Description: per oral
Study: NCT06551740
Drug: HUC2-344-R1, HUC2-344-R2
Approvals — FDA: no, EMA: no, PMDA: no
Description: per oral
Study: NCT05516550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Placebo in the morning and in the evening daily during 4 weeks
Study: NCT06475872
Drug: Crecheck Tablet 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets orally once a day
Study: NCT06475872
Drug: Crestor Tablet 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet orally once a day
Study: NCT05597462
Drug: Minocycline hydrochloride capsules
Normalized name: Minocycline Hydrochloride Capsules
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline hydrochloride capsules, 40 mg will be administered orally once daily for 16 weeks.
Study: NCT06119672
Drug: Probiotic Blend Oral capsules
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: probtiotic bend oral tablets from biovia will be adminestrated containing 4 strains ( twice daily) in addition to topical clobetasol application twice daily
Study: NCT06119672
Drug: Corticosteroids for Local Oral Treatment
Normalized name: Corticosteroids for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical clobetasol probionate in orabase application 4 times daily
Study: NCT05483634
Drug: Vaginal estrogen supplement
Normalized name: estrogens, conjugated (USP) Vaginal Cream [Premarin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vaginal estrogen supplement, then twice per week. Continue for three months.
Study: NCT06266715
Drug: ATP Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cap escitalopram 10mg OD for four weeks and injection ATP 100mg in 100ml NS BD for two weeks.
Study: NCT06266715
Drug: Placebo Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cap escitalopram 10mg OD for four weeks and injection110ml NS BD for two weeks.
Study: NCT05556005
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch tablets used twice daily
Study: NCT04310423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched to endotoxin
Study: NCT06382961
Drug: Sufentanil injection
Normalized name: sufentanil Injection
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 μg.kg-1 sufentanil is injected through intravenous patient controlled anesthesia pump in a 2 ml bolus with 20 minutes lock-out, and a background infusion rate of 2 ml per hour.
Study: NCT04716595
Drug: K-877 ER 0.2 mg/day morning administration (once daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 ER 0.2 mg tablet
Study: NCT04716595
Drug: K-877 ER 0.2 mg/day evening administration (once daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 ER 0.2 mg tablet
Study: NCT06422039
Drug: HRS-7535（D）Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: One HRS-7535（D）Tablet is administered to healthy subjects.
Study: NCT06422039
Drug: HRS-7535（C）Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two HRS-7535（C）Tablets is administered to healthy subjects.
Study: NCT00343954
Drug: L-citrulline tablets, 1000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05393284
Drug: OPL-0401 Dose 1
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical Form: Capsule; Route of Administration: Oral
Study: NCT05393284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical Form: Capsule; Route of Administration: Oral
Study: NCT06175663
Drug: Antihypertensive medication withdrawal
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: To determine if high blood pressure is caused by an overproduction of aldosterone in the adrenal gland (i.e. primary hyperaldosteronism), the plasma aldosterone/renin ratio (ARR) can be determined. Because many common hypertensive drugs are known to interfere with this ratio, patients often have to discontinue drugs prior to screening or switch to drugs that are known not to affect ARR (i.e. doxazosin, verapamil, diltiazem, hydralazine). Drugs have to be stopped for at least four weeks (for mineralocorticoid receptor antagonists) or two weeks (for diuretics, Angiotensin Converting Enzyme (ACE) inhibitors, Angiotensin Receptor Blockers (ARBs)). This often leads to a temporary increase in blood pressure. After diagnostics are completed, medication is adjusted accordingly and blood pressure levels drop again.
Study: NCT05468203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days
Study: NCT05122754
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bictegravir/emtricitabine/tenofovir alafenamide once daily, 1 tablet at a time, with or without food for 48 weeks.
Study: NCT05122754
Drug: TDF-based triple ART regimen switching to B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate was administered once daily, one tablet at a time, with or without food. After Week 24, control subjects were also switched to bictegravir/emtricitabine/tenofovir alafenamide once daily, one tablet at a time, with or without food for the later 24 weeks.
Study: NCT05634057
Drug: Anisodamine hydrobromide combined with heparin
Normalized name: heparin, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: The anisodamine hydrobromide combined with heparin treatment group is on the basis of conventional treatment.
Study: NCT04623710
Drug: ALXN2050
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
Study: NCT05027997
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral matching placebo tablet
Study: NCT04807829
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive placebo comparator
Study: NCT04629144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both arms will have the same corticosteroid tapering scheme, with an initial dose of 30 mg/day. The following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive:~* 30 mg/day week (W)0-W2,~* 20 mg/day W2-W4~* 15 mg/day W4-W6,~* 10 mg/day W6-W8,~* 5 mg/day W8-W10~Between W10-W12 the strategy for stopping glucocorticoids is left to the investigator's discretion.~Stopping glucocorticoid therapy at W12. At each step, the prednisone dose will be reduced only in the absence of signs of vasculitis activity.
Study: NCT06598722
Drug: BCL-2 inhibitors combined with the HyperCVAD regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCL-2 inhibitors combined with the HyperCVAD regimen for newly diagnosed adult T-ALL/LBL
Study: NCT06605495
Drug: Modern Western Medicine
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referring to the Chinese Expert Consensus on Dry Eye: Treatment (2020), this course of treatment totaled 6 weeks.
Study: NCT05244551
Drug: ABSK061
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the escalation part, patients will receive a single dose of oral ABSK061 on C1D1 only, and then BID dosing for the rest of the days of cycle 1 and in subsequent cycles (28-day cycles). The starting dose is 5 mg BID. In the expansion part, patients will each receive oral ABSK061 at the RDE in repeated 28-day cycles.
Study: NCT06615596
Drug: Anticoagulant drugs
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the continuation arm will receive oral anticoagulant drugs such as dabigatran, rivaroxaban, apixaban, warfarin, etc. tailored to their specific risk profiles. The discontinuation arm will cease anticoagulation therapy following randomization. Smart wearable devices will monitor for AF recurrence, and patients will be followed for 24 months, with primary endpoints including thromboembolic and bleeding events.
Study: NCT06632262
Drug: ABSK061 + ABSK043
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with fibroblast growth factor receptor (FGFR) mutations and FGFR gene fusions will receive a dose of ABSK061 + ABSK043 oral capsule until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.
Study: NCT05932459
Drug: Deuremidevir Hydrobromide for Suspension 100mg
Normalized name: hydrobromic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it with 240ml water in fasted condition.
Study: NCT05932459
Drug: Deuremidevir Hydrobromide for Suspension 300mg
Normalized name: hydrobromic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it with water in fasted condition or after taking infant formula.
Study: NCT05932459
Drug: Deuremidevir Hydrobromide for Suspension 25mg
Normalized name: hydrobromic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it with 240ml water on an empty stomach.
Study: NCT05932459
Drug: Deuremidevir Hydrobromide tablets 100mg
Normalized name: hydrobromic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it with 240ml water in fasted condition.
Study: NCT05317689
Drug: Sublingual Psilocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.18mg - 4.36mg sublingual psilocin with psychological support and physiological monitoring
Study: NCT06267274
Drug: LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of ophthalmic solution instill in both eyes every night at 10:00 pm (±1 hours) for 42 days (6 weeks) (± 4 days) as per the randomization schedule.
Study: NCT05845008
Drug: Acetaminophen/Naproxen Sodium Fixed Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen/naproxen sodium fixed combination tablets, oral.
Study: NCT06423261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation administration
Study: NCT05485753
Drug: GNC-038
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion
Study: NCT06137014
Drug: Fortified Oral Rehydration Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution with reduced glucose and added amino acids.
Study: NCT03939104
Drug: Artemether-lumefantrine+placebo
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets.
Study: NCT05624320
Drug: AGN-190584
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: miotic for treatment of presbyopia
Study: NCT05099666
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage per protocol, IV per institutional standards of practice and the FDA package insert, schedule per protocol
Study: NCT06180057
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two capsules were administered orally
Study: NCT05383378
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection in the abdomen
Study: NCT05402059
Drug: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any kind of treatment or observation (no treatment) initiated or planned in accordance with current clinical practice